Hypomelanotic Disorder Overview

Save information for later
Sign Up

Learn About Hypomelanotic Disorder

What is the definition of Hypomelanotic Disorder?
Hypomelanotic disorder is a term that refers to types of skin conditions in which melanocytes (pigment cells) have a loss of pigment. Types of hypomelanotic disorders include vitiligo, ash leaf spots, and idiopathic guttate hypomelanosis, among others.
What are the symptoms of Hypomelanotic Disorder?
Symptoms of hypomelanotic disorders include loss of pigmentation that varies by the type of disorder. Symptoms of vitiligo include a complete loss of pigment in the skin that appears as well-delineated spots and patches. Symptoms of ash leaf spots include oval flattened areas of skin that lack pigment and angiofibromas on the face. Symptoms of idiopathic guttate hypomelanosis include small white flattened areas on sun-exposed skin areas.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Hypomelanotic Disorder?
Treatment for hypomelanotic disorders depends on the type. Treatment for vitiligo may include corticosteroids, tacrolimus, pimecrolimus, ultraviolet B and PUVA therapy, self-tanning creams, and skin grafting. Treatment for ash leaf spots may include laser therapy. Treatment for idiopathis guttate hypomelanosis is not necessary.
Who are the top Hypomelanotic Disorder Local Doctors?
Amit G. Pandya
Elite in Hypomelanotic Disorder
Dr. Amit G. Pandya
Dermatology
Elite in Hypomelanotic Disorder
Dr. Amit G. Pandya
Dermatology

Sunnyvale Center (401)

401 Old San Francisco Road, Level 2, 
Sunnyvale, CA 
650-934-7676
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Amit Pandya is a Dermatologist in Sunnyvale, California. Dr. Pandya is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. His top areas of expertise are Vitiligo, Hypomelanotic Disorder, Porphyria Cutanea Tarda, Melasma, and Thrombectomy. Dr. Pandya is currently accepting new patients.

Anuradha Bishnoi
Elite in Hypomelanotic Disorder
Dr. Anuradha Bishnoi
Dermatology
Elite in Hypomelanotic Disorder
Dr. Anuradha Bishnoi
Dermatology

UPMC North Hills Dermatology

9000 Brooktree Road, Suite 200, 
Wexford, PA 
724-933-1320
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Anuradha Bishnoi is a Dermatologist in Wexford, Pennsylvania. Dr. Bishnoi is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. Her top areas of expertise are Hypomelanotic Disorder, Vitiligo, Lichen Planus, and Melasma. Dr. Bishnoi is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hypomelanotic Disorder
Dr. Iltefat Hamzavi
Dermatology
Elite in Hypomelanotic Disorder
Dr. Iltefat Hamzavi
Dermatology

Hamzavi Dermatology

43151 Dalcoma Drive, Suite 4, 
Clinton Township, MI 
586-286-8720
Experience:
30+ years
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Accepting New Patients

Iltefat Hamzavi is a Dermatologist in Clinton Township, Michigan. Dr. Hamzavi has been practicing medicine for over 30 years and is rated as an Elite provider by MediFind in the treatment of Hypomelanotic Disorder. His top areas of expertise are Vitiligo, Hidradenitis Suppurativa, Hypomelanotic Disorder, and Acne. Dr. Hamzavi is currently accepting new patients.

View All Doctors
What are the latest Hypomelanotic Disorder Clinical Trials?
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug, Other
Study Phase: Phase 2

Summary: Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin color (melanin). This leads to the formation of patches of skin with less or no pigment (depigmentation). These patches can occur anywhere on the body. In the nonsegmental f...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
A Phase 3, Randomized, Double-Blind, Efficacy, and Safety Study of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to \< 12 years old) with nonsegmental vitiligo.

View All Clinical Trials